← Back to Search

Anti-tumor antibiotic

Minnelide™ 001 for Cancer

Phase 1
Waitlist Available
Research Sponsored by Minneamrita Therapeutics LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights
No Placebo-Only Group

Summary

The primary objective of this study is to determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLT) of Minnelide™ and to establish the dose of Minnelide™ recommended for future phase 2 protocol

Eligible Conditions
  • Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
To determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLT) of Minnelide™
To establish the dose of Minnelide™ recommended for future phase 2 protocol
Secondary study objectives
To determine pharmacodynamic effect of Minnelide™ on HSP70 levels. And to explore pharmacodynamics effect of Minnelide™ on PET Scans and using Choi criteria on the CT scans.
To determine the pharmacokinetics of Minnelide™
To observe patients for any evidence of antitumor activity of Minnelide™ per RECIST criteria

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Minnelide™ 001Experimental Treatment1 Intervention
A Phase 1, Multi-Center, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide™ given daily for 21 days followed by 7 days off schedule in patients with Advanced GI Tumors
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Minnelide™ 001
2013
Completed Phase 1
~50

Find a Location

Who is running the clinical trial?

Minneamrita Therapeutics LLCLead Sponsor
6 Previous Clinical Trials
184 Total Patients Enrolled
Mohana Velagapudi, MDStudy DirectorMinneamrita Therapeutics LLC
Linda Vocila, BSNStudy DirectorTranslational Drug Development
~4 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top